LOGIN TO YOUR ACCOUNT

Username
Password
Remember Me
Or use your Academic/Social account:

CREATE AN ACCOUNT

Or use your Academic/Social account:

Congratulations!

You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.

Important!

Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message

CREATE AN ACCOUNT

Name:
Username:
Password:
Verify Password:
E-mail:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Knispel, Edelgard (2010)
Publisher: Freie Universität Berlin Universitätsbibliothek, Garystr. 39, 14195 Berlin
Languages: German
Types: Doctoral thesis
Subjects: 610 Medizin und Gesundheit, 610 Medical sciences; Medicine
ddc: ddc:610
Background: 4 double-blind, placebo-controlled clinical phase III trials of the RIO (Rimona-bant in Obesity)-programme indicated that rimonabant, a selective cannabinoid-1 (CB1) re-ceptor blocker, promoted significant decrease of bodyweight and waist circumference in overweight or obese patients with dyslipidaemia or type 2 diabetes and improvement of insu-lin resistance and lipid and glucose profiles (van Gaal et al., 2005; Deprés et al., 2005; Pi-Sunyer et al., 2006; Scheen et al., 2006). This analysis of subgroups included in the RIO-Europe study (van Gaal et al., 2005) ad-dressed the efficacy and safety of rimonabant in therapy of obesity over 2 years. In addition to changes of physical parameters like bodyweight and waist circumference as well as lipid and glucose profiles, changes of health-related quality of life and food behaviour were evaluated. Methods: 42 overweight or obese patients with body-mass index 30 kg/m2 or greater, or body-mass index greater than 27 kg/m2 with treated or untreated hypertension, dyslipidaemia, or both, were randomized to receive placebo (n=9), 5 mg rimonabant (n=17) or 20 mg rimona-bant (n=16) once daily in addition to a hypocaloric diet and advice for physical activity for 2 years from 2001 to 2003 at the St. Hedwig hospital at Berlin. The primary endpoints and effi-cacy measures were changes over one year in body weight and waist circumference as well as in health-related parameters that were assessed by SF36- or IWQOL-Lite-health survey ques-tionnaire. Results: 38 patients completed the 1 year follow-up. Treatment with 20 mg rimonabant once daily for one year produced significant reduction in body weight (-5,8 kg vs –1,3 kg; p0,05) and in waist circumference (-6,3 cm vs –2,7 cm; p0,0001) as well as improvement of lipid (HDL-cholesterol) and glucose profile (fasting glucose) compared with placebo. Concerning long-term effects, weight loss and reduction of waist circumference achieved during year 1 were maintained during year 2 in patients receiving 20 mg of rimonabant during both years. A greater improvement in general health perception (as assessed by SF 36; p0,05) and in men-tal well-being (p0,01) were recorded at 1 year in the 20 mg/day rimonabant group than in the placebo group. Health-related quality of life was specifically assessed with IWQOL-Lite questionnaire. Im-provements at 1 year in total IWQOL-Lite score (p0,01), physical functioning (p0,01) and self-esteem (p0,01) were noted in the 20 mg/day rimonabant group. Further improvements at least in tendency were seen for all food behaviour parameters in the 20 mg/day rimonabant group at 1 year (appetite, desire for high fat foods and for sweets). Conclusions: Selective CB1 blockade with 20 mg rimonabant in combination with diet and exercise over 1 year, promoted modest but sustained reductions in body weight and waist cir-cumference in obese patients and not only favorable changes in cardiometabolic risk factors but also in perception of physical and mental health. The greater drop-out rate after 1 year treatment with placebo (67%) compared to treatment with 20 mg rimonabant (44%) can pos-sibly be explained by patient’s satisfaction that was weight dependent. The trial is limited by only few cases and high drop-out rates. Long-term effects require further study.
  • No references.
  • No related research data.
  • No similar publications.

Share - Bookmark

Cite this article